Travere Therapeutics (TVTX) EBIAT (2016 - 2025)
Historic EBIAT for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $25.7 million.
- Travere Therapeutics' EBIAT rose 14689.93% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.5 million, marking a year-over-year increase of 7480.78%. This contributed to the annual value of -$321.5 million for FY2024, which is 1455.84% up from last year.
- Latest data reveals that Travere Therapeutics reported EBIAT of $25.7 million as of Q3 2025, which was up 14689.93% from -$12.8 million recorded in Q2 2025.
- Over the past 5 years, Travere Therapeutics' EBIAT peaked at $150.7 million during Q3 2023, and registered a low of -$136.1 million during Q1 2024.
- Over the past 5 years, Travere Therapeutics' median EBIAT value was -$70.4 million (recorded in 2024), while the average stood at -$54.6 million.
- In the last 5 years, Travere Therapeutics' EBIAT plummeted by 676670.79% in 2021 and then soared by 27931.19% in 2023.
- Over the past 5 years, Travere Therapeutics' EBIAT (Quarter) stood at -$88.8 million in 2021, then rose by 3.53% to -$85.6 million in 2022, then fell by 5.3% to -$90.2 million in 2023, then surged by 33.17% to -$60.3 million in 2024, then surged by 142.66% to $25.7 million in 2025.
- Its last three reported values are $25.7 million in Q3 2025, -$12.8 million for Q2 2025, and -$41.2 million during Q1 2025.